Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $130,030.00 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Stock Up 4.1%

REGN traded up $26.42 on Tuesday, hitting $676.23. The company had a trading volume of 918,303 shares, compared to its average volume of 872,881. The stock has a fifty day moving average price of $652.48 and a 200-day moving average price of $725.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $537.45 and a 12-month high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The stock has a market capitalization of $71.49 billion, a price-to-earnings ratio of 16.48, a P/E/G ratio of 1.44 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the firm posted $8.22 earnings per share. The company’s quarterly revenue was up 19.0% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $26,000. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $26,000. Titan Wealth CI Ltd acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. Finally, Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron Pharmaceuticals (REGN) from hold to buy, signaling renewed confidence in the stock’s outlook. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Truist kept a buy rating and still sees upside, even after trimming its price target on Regeneron. Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation
• Positive Sentiment: HSBC and Cantor Fitzgerald also maintained bullish ratings on REGN, suggesting analysts still view the shares as attractive despite lower targets. Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc
• Positive Sentiment: Zacks highlighted Regeneron’s strong earnings surprise history and said the company appears positioned to beat estimates again next quarter, which can support the stock. Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Zacks also described Regeneron as a strong value stock, reinforcing the case for investors looking for quality at a reasonable valuation. Here’s Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Broader biotech sentiment was upbeat after Jim Cramer called biotech “the hottest group in the market” and suggested a pickup in M&A activity, which could lift sentiment across the sector, including REGN. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Several firms cut their price targets on Regeneron, including RBC, Truist, HSBC, and Cantor Fitzgerald, reflecting more cautious near-term expectations even though most ratings remained positive.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reduced their price target on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a research report on Monday. JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Royal Bank Of Canada reduced their target price on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a research report on Tuesday. TD Cowen increased their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Finally, BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $790.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.